- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00402194
Treating the Endothelium to Restore Insulin Sensitivity
September 20, 2013 updated by: Indiana University School of Medicine
A study of 12 weeks' treatment with losartan or placebo, to test the hypothesis that RAS inhibition will improve insulin' vascular actions and therefore improve insulin sensitivity in skeletal muscle.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Recent studies suggesting an effect of cardiovascular therapies to prevent diabetes remain unexplained.
We hypothesize that these therapies improve vascular endothelial function allowing improved actions of insulin in the vasculature, which comprise a significant portion of insulin's metabolic action.
We therefore propose to measure insulin-mediated glucose disposal and insulin-mediated vasodilation before and after 12 weeks' therapy with Losartan (an angiotensin receptor blocker) or placebo, in a randomized design.
Subjects will include 28 subjects with impaired glucose tolerance, which is generally accompanied by both insulin resistance and impaired vascular function.
With this number of participants we have a 90% chance of showing a statistically significant and clinically meaningful effect of insulin on leg vascular resistance, and an even higher chance of showing a difference in insulin's metabolic effects.
Exclusion criteria will include frank hypertension, diabetes, or hypercholesterolemia, and biochemical or other contraindications to losartan therapy.
The primary endpoint for statistical analysis will be the invasive measure of insulin-stimulated endothelial function.
We anticipate an improvement in both vascular and metabolic measures of insulin action following Losartan therapy but no change from untreated baseline following placebo.
Study Type
Interventional
Enrollment (Actual)
17
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Hospital GCRC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy
- Age 20-55
- Male and female
- Obese, defined as Males: BMI >28 or > 30% fat by DEXA scan or Bod Pod; Females: BMI >30 or > 33% fat by DEXA scan or Bod Pod
- Weight stable over at least 4 months
Exclusion Criteria:
- Diabetes mellitus (ADA criteria)
- Age <20 or > 55 yrs
- Blood pressure >160/90 or < 90/65 mmHg
- Total cholesterol >240 or LDL cholesterol >160 mg/dL
- Baseline elevations in AST or ALT > 3X ULN
- Baseline elevation in creatinine >1.6 ng/mL
- Unexplained baseline elevation in creatine kinase > 3X ULN
- Concurrent significant chronic medical illness including, but not limited to, human immunodeficiency virus infection, Syphilis, hepatitis B infection, or hepatitis C infection
- Pregnancy
- Known hypersensitivity or intolerance to the study agents
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Interventional Model: Parallel Assignment
- Masking: Quadruple
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Leg Blood Flow Response to Insulin
Time Frame: 3 months
|
3 months
|
|
Insulin-stimulated Leg Glucose Uptake
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Kieren J Mather, MD, Indiana University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2005
Primary Completion (Actual)
November 1, 2011
Study Completion (Actual)
March 1, 2012
Study Registration Dates
First Submitted
November 20, 2006
First Submitted That Met QC Criteria
November 20, 2006
First Posted (Estimate)
November 22, 2006
Study Record Updates
Last Update Posted (Estimate)
September 24, 2013
Last Update Submitted That Met QC Criteria
September 20, 2013
Last Verified
September 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Hyperinsulinism
- Hyperglycemia
- Prediabetic State
- Glucose Intolerance
- Insulin Resistance
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Losartan
Other Study ID Numbers
- IU-IRB-0301-08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.